Further Evidence of Allergic Contact Dermatitis Caused by 2,2'-Methylenebis(6- tert -Butyl-4-Methylphenol) Monoacrylate, a New Sensitizer in the Dexcom G6 Glucose Sensor.
Journal
Dermatitis : contact, atopic, occupational, drug
ISSN: 2162-5220
Titre abrégé: Dermatitis
Pays: United States
ID NLM: 101207335
Informations de publication
Date de publication:
Historique:
pubmed:
12
6
2021
medline:
22
7
2022
entrez:
11
6
2021
Statut:
ppublish
Résumé
Since the spring of 2020, we have seen several patients experiencing severe allergic contact dermatitis (ACD) from the Dexcom G6 glucose sensor after the composition of the sensor's adhesive patch had been changed. We have previously reported the finding of a new sensitizer, 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate, in the Dexcom G6 adhesive patch. Three patients with ACD from Dexcom G6 tested positive to this sensitizer. They were also allergic to isobornyl acrylate, a sensitizer present both in Dexcom G6 and in other medical devices previously used by these patients. The aim of the study was to report the first 4 cases sensitized to 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate without a simultaneous allergy to isobornyl acrylate. The cases were patch tested their own materials, a medical device series, and 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate in several concentrations. All 4 cases tested positive to 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate at either 1.0% or 1.5% in petrolatum, whereas 20 controls tested negative to both concentrations. The cases reported here provide further evidence of 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate as a relevant culprit sensitizer in patients with ACD from Dexcom G6. However, the initially used patch test concentration (0.3%) did not suffice to elicit positive reactions in these cases, which is why patch testing at 1.5% is recommended.
Sections du résumé
BACKGROUND
BACKGROUND
Since the spring of 2020, we have seen several patients experiencing severe allergic contact dermatitis (ACD) from the Dexcom G6 glucose sensor after the composition of the sensor's adhesive patch had been changed. We have previously reported the finding of a new sensitizer, 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate, in the Dexcom G6 adhesive patch. Three patients with ACD from Dexcom G6 tested positive to this sensitizer. They were also allergic to isobornyl acrylate, a sensitizer present both in Dexcom G6 and in other medical devices previously used by these patients.
OBJECTIVE
OBJECTIVE
The aim of the study was to report the first 4 cases sensitized to 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate without a simultaneous allergy to isobornyl acrylate.
METHODS
METHODS
The cases were patch tested their own materials, a medical device series, and 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate in several concentrations.
RESULTS
RESULTS
All 4 cases tested positive to 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate at either 1.0% or 1.5% in petrolatum, whereas 20 controls tested negative to both concentrations.
CONCLUSIONS
CONCLUSIONS
The cases reported here provide further evidence of 2,2'-methylenebis(6- tert -butyl-4-methylphenol) monoacrylate as a relevant culprit sensitizer in patients with ACD from Dexcom G6. However, the initially used patch test concentration (0.3%) did not suffice to elicit positive reactions in these cases, which is why patch testing at 1.5% is recommended.
Identifiants
pubmed: 34115662
doi: 10.1097/DER.0000000000000767
pii: 01206501-900000000-99467
doi:
Substances chimiques
Acrylates
0
Adhesives
0
Allergens
0
Cresols
0
Phenols
0
4-cresol
1MXY2UM8NV
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-292Informations de copyright
Copyright © 2022 American Contact Dermatitis Society. All Rights Reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Berg AK, Norgaard K, Thyssen JP, et al. Skin problems associated with insulin pumps and sensors in adults with type 1 diabetes: a cross-sectional study. Diabetes Technol Ther 2018;20:475–482.
Berg AK, Olsen BS, Thyssen JP, et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr Diabetes 2018;19:733–740.
Asarani NAM, Reynolds AN, Boucher SE, et al. Cutaneous complications with continuous or flash glucose monitoring use: systematic review of trials and observational studies. J Diabetes Sci Technol 2020;14:328–337.
Herman A, Aerts O, Baeck M, et al. Allergic contact dermatitis caused by isobornyl acrylate in FreeStyle® Libre, a newly introduced glucose sensor. Contact Dermatitis 2017;77:367–373.
Mowitz M, Herman A, Baeck M, et al. N , N -dimethylacrylamide—a new sensitizer in the FreeStyle Libre glucose sensor. Contact Dermatitis 2019;81(1):27–31.
Peeters C, Herman A, Goossens A, et al. Allergic contact dermatitis caused by 2-ethyl cyanoacrylate contained in glucose sensor sets in two diabetic adults. Contact Dermatitis 2017;77:426–429.
Hamnerius N, Mowitz M. Intense skin reaction to a new glucose monitoring and insulin pump system. Contact Dermatitis 2020;83:524–527.
Svedman C, Ulriksdotter J, Lejding T, et al. Changes in adhesive ingredients in continuous glucose monitoring systems may induce new contact allergy pattern. Contact Dermatitis 2021;84:439–446.
Hartsough EM, Hylwa SA. Wearable woes: allergens in diabetic devices. Dermatitis 2021;32:19–31.
Raison-Peyron N, Mowitz M, Bonardel N, et al. Allergic contact dermatitis caused by isobornyl acrylate in Omnipod, an innovative tubeless insulin pump. Contact Dermatitis 2018;79:76–80.
Herman A, Baeck M, de Montjoye L, et al. Allergic contact dermatitis caused by isobornyl acrylate in the Enlite glucose sensor and the Paradigm MiniMed Quick-set insulin infusion set. Contact Dermatitis 2019;81:432–437.
Svedman C, Bruze M, Antelmi A, et al. Continuous glucose monitoring systems give contact dermatitis in children and adults despite efforts of providing less “allergy-prone” devices: investigation and advice hampered by insufficient material for optimized patch test investigations. J Eur Acad Dermatol Venereol 2021;35:730–737.
Aerts O, Herman A, Mowitz M, et al. Isobornyl acrylate. Dermatitis 2020;31:4–12.
Ulriksdotter J, Svedman C, Bruze M, et al. Contact dermatitis caused by glucose sensors—15 adult patients tested with a medical device patch test series. Contact Dermatitis 2020;83:301–309.
Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis 2015;73:195–221.
Bruze M. The use of ultrasonic bath extracts in the diagnostics of contact allergy and allergic contact dermatitis. In: Lachapelle JM, Bruze M, Elsner P, eds. Patch Testing Tips . Berlin, Germany: Springer; 2014:129–142.
Fregert S. Manual of Contact Dermatitis . Copenhagen, Denmark: Munksgaard; 1981.
Mowitz M, Fornander L, Hosseiny S, et al. Patch testing with isobornyl acrylate in 16 Swedish patients with contact dermatitis from glucose sensors and/or insulin pumps. Acta Derm Venereol 2019;99:1286–1287.
Oppel E, Kamann S, Reichl FX, et al. The Dexcom glucose monitoring system—an isobornyl acrylate-free alternative for diabetic patients. Contact Dermatitis 2019;81:32–36.
Kamann S, Oppel E, Liu F, et al. Evaluation of isobornyl acrylate content in medical devices for diabetes treatment. Diabetes Technol Ther 2019;21:533–537.
Dexcom Inc. Field safety Notice | Dexcom G6 Sensor. FAS-SD-20-003. Advise from manufacturer. Available at: https://mhra-gov.filecamp.com/s/ZbG4ysnmVLH9Evvq/d . 2020. Accessed February 19, 2021.
Bruze M, Conde-Salazar L, Goossens A, et al. Thoughts on sensitizers in a standard patch test series. The European Society of Contact Dermatitis. Contact Dermatitis 1999;41:241–250.
Kanerva L, Estlander T, Jolanki R. Sensitization to patch test acrylates. Contact Dermatitis 1988;18:10–15.
Bruze M, Gruvberger B, Björkner B, et al. An unusual contact sensitizer. In: Maibach HI, Menne T, eds. Exogenous Dermatoses . Boca Raton, FL: CRC Press Inc; 1990:283–298.
Bruze M, Engfeldt M, Goncalo M, et al. Recommendation to include methylisothiazolinone in the European Baseline Patch Test Series—on behalf of the European Society of Contact Dermatitis and the European Environmental and Contact Dermatitis Research Group. Contact Dermatitis 2013;69:263–270.
Ulriksdotter J, Mowitz M, Svedman C, et al. Patch testing and diagnosis when suspecting allergic contact dermatitis from medical devices. Contact Dermatitis 2020;83:333–335.
Aschenbeck KA, Hylwa SA. A diabetic's allergy: ethyl cyanoacrylate in glucose sensor adhesive. Dermatitis 2017;28:289–291.
Gisin V, Chan A, Welsh JB. Manufacturing process changes and reduced skin irritations of an adhesive patch used for continuous glucose monitoring devices. J Diabetes Sci Technol 2018;12:725–726.
Bruze M, Dahlquist I, Fregert S. Patch testing with colophony at 60% concentration. Contact Dermatitis 1986;15:193.
Passanisi S, Lombardo F, Barbalace A, et al. Allergic contact dermatitis and diabetes medical devices: 2 clinical cases. Contact Dermatitis 2018;79:115–117.
Dexcom Inc. How can I avoid irritated or sensitive skin caused by the Dexcom sensor adhesive? Available at: https://www.dexcom.com/faqs/sensitive-skin . Accessed March 11, 2021.
Huang C, DeKoven J. An unexpected source of glucose monitor-associated allergic contact dermatitis [published online February 17, 2021]. Contact Dermatitis 2021. doi: https://doi.org/10.1111/cod.13815 .
doi: 10.1111/cod.13815
Kamann S, Heinemann L, Oppel E. Usage of hydrocolloid-based plasters in patients who have developed allergic contact dermatitis to isobornyl acrylate while using continuous glucose monitoring systems. J Diabetes Sci Technol 2020;14:582–585.
Pyl J, Dendooven E, Van Eekelen I, et al. Prevalence and prevention of contact dermatitis caused by FreeStyle Libre: a monocentric experience. Diabetes Care 2020;43:918–920.
Ashworth J, Booker J, Breathnach SM. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br J Dermatol 1988;118:457–469.
Seyfarth F, Elsner P, Tittelbach J, et al. Contact allergy to mometasone furoate with cross-reactivity to group B corticosteroids. Contact Dermatitis 2008;58:180–181.